摘要 |
<p>This invention provides methods of inhibiting HIV-I infection of a susceptible cell by an HIV- 1 virus that is, or has become, resistant to one or more HIV protease inhibitors; one or more HIV reverse transcriptase inhibitors; one or more fusion inhibitors; one or more non-antibody CCR5 anatagonist inhibitors of the interaction of HIV-I gpl20 and CCR5; or one or more HIV protease inhibitors and one or more HIV reverse transcriptase inhibitors, which comprise subjecting the susceptible cell to an effective HIV-I infection inhibiting dose of a humanized antibody designated PRO 140, or of an anti-CCR5 receptor monoclonal antibody, wherein the effective HIV-I infection inhibiting dose comprises from 0.1 mg per kg to 25 mg per kg of the subject's body weight, so as to thereby inhibit the infection of the susceptible cell by HIV-I that is, or has become, resistant to one or more of the aforementioned inhibitors.</p> |
申请人 |
PROGENICS PHARMACEUTICALS, INC.;OLSON, WILLIAM, C.;KETAS, THOMAS, J.;MAROZSAN, ANDRE |
发明人 |
OLSON, WILLIAM, C.;KETAS, THOMAS, J.;MAROZSAN, ANDRE |